Novocure获FDA批准,电场疗法瞄准胰腺癌治疗。
Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer
生物技术与制药领域的最新动态
Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer
Mondrian Investment Partners LTD Makes New $1.40 Million Investment in Waters Corporation $WAT - MarketBeat
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy
Shell Asset Management Co. Has $742,000 Stock Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat
How to evaluate prospective diagnostic laboratory partners for your patient support program
Selecting the optimal cell therapy manufacturing platform
Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse
Thermo Fisher Scientific expands real-world data interoperability and linkage through partnership with Datavant - SelectScience
Spatially periodic computation in the entorhinal-hippocampal circuit during navigation
Linking spinal circuit reorganization to recovery after thoracic spinal cord injury
Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of Pseudomonas aeruginosa act through distinct mechanisms
Kinematics and morphological correlates of descent strategies in arboreal mammals suggest early upright postures in euprimates
Decoding early synaptic failure in Alzheimer’s disease through multiomic analysis - Illumina
Illumina’s AI-Driven Data Vision Is Expanding — Will Multiomics Integration Unlock a Transformational Edge? - Smartkarma
Agilent Technologies (A) Valuation Check After FDA Expansion Of Keytruda Companion Diagnostic - simplywall.st
Illumina: Weak Backlog Support and Rising Competitive Pressures Undermine 2026 Outlook, Justifying Sell Rating - TipRanks
The future of global food security may depend on quality agrigenomics software - Illumina
People On The Move: Appointments At Sanofi, Lonza, SkinBioTherapeutics - Citeline News & Insights
Agilent Technologies (A) Stock Analysis: Unpacking A 34.86% Potential Upside For Investors - DirectorsTalk Interviews
Zymedi describes new KARS1 inhibitors for cancer metastasis